Tel. +49 203 / 555 858 -31 / 32 / 33 · Fax: +49 203 / 35 82 99
21.01.2020
Genekam has developed novel corona virus 2020 (Wuhan strain specific) kits and potential therapeutic molecules.
21.01.2020
3D Genomemedicine Inc is going to operate in USA
Genekam is developing complex solutions based on antibody conjugates for therapeutic and diagnostic use. The antibodies can be recombinant as well as monoclonal type. Conjugates will be based on beyond the state of art technology. Some of conjugates may have potential to be used as vaccines also.